Drug
Alxn2030
Alxn2030: highest development phase Phase 2, developed by Alexion. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Alexion
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALXN2030 NCT06744647 | Phase 2 | Antibody-Mediated Rejection |
Latest
No recent events.
Follow Alxn2030 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.